What did @taylormaemcd actually say?
In this week 8 update, the creator says she's been on a GLP-1 for five months total, lost 40 pounds on semaglutide, and is now down 21 pounds on compounded tirzepatide while staying at the 7.5 mg dose. She also says she has "not a single side effect" beyond suppressed food noise, and she walks viewers through an arm injection, noting anxiety about injecting anywhere other than her stomach. That's the core of it: a personal progress report, a live injection demo, and a bold claim about tolerability.
Worth noting upfront: she refers to the medication as "compound a torsepitide" in speech, which is a pronunciation variation of compounded tirzepatide. The video is clearly about that compound, not a branded product like Mounjaro or Zepbound.
Does the science back this up?
The weight loss numbers she describes are plausible but sit at the high end of what clinical data typically shows for tirzepatide at this timeframe. The "zero side effects" claim is where the science pushes back hardest.
In the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine), tirzepatide at 15 mg produced mean weight loss of about 20.9% of body weight over 72 weeks. At 7.5 mg, the effect is meaningful but more modest. Losing 21 pounds in eight weeks on tirzepatide is possible, especially with carryover effects from prior semaglutide use, but it's not the average experience.
On tolerability: SURMOUNT-1 found that roughly 80% of participants on tirzepatide reported at least one gastrointestinal side effect, with nausea affecting around 30% at the 10 mg and 15 mg doses. Side effects are most common during dose escalation. Staying at 7.5 mg for eight weeks, as she has, may genuinely reduce GI burden for some people. But "not a single side effect" is an unusual report, not a typical one.
What did they get wrong (or right)?
Let's be direct. The injection site rotation she demonstrates, moving between the stomach and arm, is actually correct practice. The FDA-approved prescribing information for tirzepatide lists the abdomen, thigh, and upper arm as acceptable injection sites. Her anxiety about arm injections is relatable and the technique she describes, ensuring the needle seated properly, reflects real-world self-injection concerns that are worth airing publicly.
Where she oversimplifies: the claim that suppressed food noise is a side effect is a bit backwards. Appetite suppression is the intended pharmacological action of GLP-1 and GIP receptor agonism, not a side effect. Calling it one conflates mechanism with adverse event, and that framing could mislead viewers who expect to feel nothing on these medications.
The bigger issue is the zero-side-effects claim. It may be her genuine experience, but presenting it as a norm without context could set unrealistic expectations. Research consistently shows most patients experience some GI symptoms, particularly in earlier weeks (Frías et al., 2021, The Lancet).
What should you actually know?
Compounded tirzepatide is not the same as Mounjaro or Zepbound. Compounded versions are not FDA-approved, are not bioequivalent in any regulatory sense, and their purity and dosing consistency depend entirely on the compounding pharmacy's standards. That distinction matters, and this video does not address it.
The weight loss she reports, 40 pounds on semaglutide followed by 21 more on tirzepatide, is within biological possibility but assumes several things: consistent diet behavior, accurate self-reporting, and no water weight misattribution. It is not a benchmark for what viewers should expect.
On injection anxiety: it's extremely common. A 2020 review in Diabetes Technology and Therapeutics found that needle anxiety affects a significant portion of patients on injectable therapies and contributes to non-adherence. Her willingness to show real-time uncertainty is one of the more genuinely useful things about this video.
If you're considering a GLP-1, the most important variables are not someone else's pound count. They are your baseline metabolic health, how your prescriber manages dose titration, and whether the pharmacy dispensing your compound is operating under appropriate oversight.